 Marco Del Chiaro
Concepts (539)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pancreatic Neoplasms | 139 | 2024 | 734 | 31.550 |
Why?
| | Carcinoma, Pancreatic Ductal | 60 | 2023 | 210 | 16.910 |
Why?
| | Pancreatectomy | 56 | 2024 | 165 | 15.180 |
Why?
| | Pancreaticoduodenectomy | 28 | 2023 | 128 | 6.500 |
Why?
| | Pancreas | 36 | 2023 | 282 | 4.630 |
Why?
| | Adenocarcinoma | 18 | 2023 | 812 | 4.320 |
Why?
| | Adenocarcinoma, Mucinous | 14 | 2023 | 59 | 4.020 |
Why?
| | Neoadjuvant Therapy | 22 | 2023 | 333 | 3.890 |
Why?
| | Pancreatic Cyst | 10 | 2023 | 47 | 2.820 |
Why?
| | Pancreatic Fistula | 11 | 2023 | 21 | 2.510 |
Why?
| | Pancreatic Ducts | 10 | 2022 | 66 | 2.070 |
Why?
| | Common Bile Duct Neoplasms | 5 | 2023 | 23 | 2.060 |
Why?
| | Ampulla of Vater | 5 | 2023 | 28 | 2.060 |
Why?
| | Carcinoma, Papillary | 8 | 2019 | 76 | 2.030 |
Why?
| | Exocrine Pancreatic Insufficiency | 5 | 2019 | 17 | 1.800 |
Why?
| | Humans | 207 | 2024 | 118972 | 1.760 |
Why?
| | Early Detection of Cancer | 6 | 2021 | 360 | 1.700 |
Why?
| | Retrospective Studies | 73 | 2024 | 12978 | 1.680 |
Why?
| | Gastrointestinal Neoplasms | 2 | 2023 | 61 | 1.590 |
Why?
| | Mesenteric Artery, Superior | 4 | 2020 | 12 | 1.480 |
Why?
| | Pancreas Transplantation | 24 | 2010 | 68 | 1.460 |
Why?
| | Aged | 68 | 2023 | 19657 | 1.430 |
Why?
| | Pancreatitis, Chronic | 6 | 2020 | 39 | 1.300 |
Why?
| | Vascular Surgical Procedures | 3 | 2021 | 262 | 1.290 |
Why?
| | Portal Vein | 8 | 2021 | 90 | 1.260 |
Why?
| | Quality of Life | 7 | 2023 | 2366 | 1.220 |
Why?
| | Middle Aged | 75 | 2023 | 27617 | 1.220 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 8 | 2023 | 1390 | 1.210 |
Why?
| | Islets of Langerhans | 5 | 2020 | 739 | 1.110 |
Why?
| | Carcinoma, Neuroendocrine | 2 | 2023 | 31 | 1.100 |
Why?
| | Endosonography | 5 | 2021 | 142 | 1.080 |
Why?
| | Prognosis | 21 | 2023 | 3443 | 1.070 |
Why?
| | Aged, 80 and over | 39 | 2021 | 6561 | 1.070 |
Why?
| | Postoperative Complications | 27 | 2023 | 2235 | 1.040 |
Why?
| | Treatment Outcome | 37 | 2023 | 9342 | 1.020 |
Why?
| | Precancerous Conditions | 3 | 2015 | 160 | 1.020 |
Why?
| | Male | 89 | 2023 | 57801 | 0.990 |
Why?
| | Nomograms | 2 | 2022 | 48 | 0.980 |
Why?
| | Duodenal Neoplasms | 3 | 2023 | 18 | 0.960 |
Why?
| | CA-19-9 Antigen | 3 | 2022 | 14 | 0.950 |
Why?
| | Mesenteric Veins | 3 | 2021 | 10 | 0.950 |
Why?
| | Neoplasms, Cystic, Mucinous, and Serous | 3 | 2023 | 24 | 0.950 |
Why?
| | Female | 85 | 2023 | 61564 | 0.920 |
Why?
| | Minimally Invasive Surgical Procedures | 3 | 2020 | 158 | 0.860 |
Why?
| | Survival Rate | 11 | 2023 | 1720 | 0.840 |
Why?
| | Biomarkers, Tumor | 10 | 2022 | 1059 | 0.830 |
Why?
| | Surgical Stapling | 1 | 2021 | 9 | 0.800 |
Why?
| | Adult | 60 | 2022 | 31512 | 0.800 |
Why?
| | Organ Transplantation | 2 | 2023 | 165 | 0.790 |
Why?
| | Absorbable Implants | 1 | 2021 | 35 | 0.780 |
Why?
| | Neoplasm Recurrence, Local | 4 | 2023 | 900 | 0.770 |
Why?
| | Angiotensin-Converting Enzyme Inhibitors | 1 | 2022 | 195 | 0.770 |
Why?
| | Risk Assessment | 10 | 2021 | 3057 | 0.760 |
Why?
| | Cystadenocarcinoma, Mucinous | 2 | 2018 | 13 | 0.760 |
Why?
| | Neoplasm Invasiveness | 7 | 2020 | 462 | 0.750 |
Why?
| | Neoplasms, Second Primary | 2 | 2019 | 93 | 0.750 |
Why?
| | Vascular Neoplasms | 1 | 2020 | 16 | 0.730 |
Why?
| | Neoplasms, Multiple Primary | 3 | 2015 | 56 | 0.730 |
Why?
| | Pancreatitis | 5 | 2022 | 108 | 0.720 |
Why?
| | Arteries | 2 | 2019 | 250 | 0.720 |
Why?
| | Adenocarcinoma, Papillary | 2 | 2017 | 9 | 0.710 |
Why?
| | Neoplasm Staging | 10 | 2023 | 1223 | 0.700 |
Why?
| | Endocrine System Diseases | 1 | 2019 | 32 | 0.700 |
Why?
| | Thrombelastography | 1 | 2020 | 192 | 0.700 |
Why?
| | Neuroendocrine Tumors | 4 | 2023 | 83 | 0.690 |
Why?
| | Practice Guidelines as Topic | 3 | 2021 | 1440 | 0.660 |
Why?
| | Chemotherapy, Adjuvant | 8 | 2023 | 360 | 0.640 |
Why?
| | Follow-Up Studies | 18 | 2022 | 4596 | 0.630 |
Why?
| | Metabolomics | 2 | 2019 | 550 | 0.620 |
Why?
| | Patient Compliance | 1 | 2021 | 537 | 0.610 |
Why?
| | Europe | 8 | 2021 | 356 | 0.610 |
Why?
| | Neoplasm Metastasis | 1 | 2019 | 544 | 0.590 |
Why?
| | Kidney Transplantation | 17 | 2016 | 585 | 0.590 |
Why?
| | Hepatic Artery | 4 | 2020 | 55 | 0.580 |
Why?
| | Celiac Artery | 4 | 2020 | 9 | 0.570 |
Why?
| | Living Donors | 3 | 2016 | 319 | 0.570 |
Why?
| | Watchful Waiting | 1 | 2016 | 55 | 0.570 |
Why?
| | Hepatitis B virus | 1 | 2016 | 25 | 0.560 |
Why?
| | Pancreaticojejunostomy | 3 | 2022 | 5 | 0.560 |
Why?
| | Evidence-Based Medicine | 4 | 2021 | 693 | 0.550 |
Why?
| | Patient Selection | 8 | 2014 | 676 | 0.540 |
Why?
| | Hypothermia, Induced | 1 | 2016 | 68 | 0.540 |
Why?
| | Cohort Studies | 11 | 2024 | 5116 | 0.520 |
Why?
| | Disease Progression | 4 | 2022 | 2490 | 0.520 |
Why?
| | Pancreatic Diseases | 3 | 2020 | 63 | 0.510 |
Why?
| | Organ Sparing Treatments | 1 | 2015 | 31 | 0.510 |
Why?
| | Carcinoma, Hepatocellular | 1 | 2016 | 227 | 0.490 |
Why?
| | Antineoplastic Agents | 6 | 2021 | 1974 | 0.480 |
Why?
| | Palliative Care | 3 | 2019 | 629 | 0.480 |
Why?
| | Clinical Trials as Topic | 1 | 2018 | 969 | 0.470 |
Why?
| | Cholangiopancreatography, Endoscopic Retrograde | 4 | 2019 | 176 | 0.470 |
Why?
| | Cystadenocarcinoma | 1 | 2013 | 2 | 0.460 |
Why?
| | Cystadenoma | 1 | 2013 | 4 | 0.460 |
Why?
| | Robotics | 1 | 2014 | 83 | 0.450 |
Why?
| | Prospective Studies | 14 | 2022 | 6471 | 0.440 |
Why?
| | Autoimmune Diseases | 3 | 2021 | 398 | 0.440 |
Why?
| | Tomography, X-Ray Computed | 10 | 2021 | 2436 | 0.440 |
Why?
| | Cystadenoma, Serous | 3 | 2020 | 17 | 0.440 |
Why?
| | Italy | 11 | 2013 | 90 | 0.430 |
Why?
| | Diabetes Mellitus | 3 | 2019 | 942 | 0.430 |
Why?
| | Incidence | 8 | 2019 | 2424 | 0.420 |
Why?
| | Dilatation, Pathologic | 3 | 2020 | 56 | 0.410 |
Why?
| | Combined Modality Therapy | 4 | 2023 | 1166 | 0.400 |
Why?
| | Diagnosis, Differential | 7 | 2022 | 1384 | 0.400 |
Why?
| | Gastroenterology | 2 | 2023 | 158 | 0.390 |
Why?
| | Risk Factors | 15 | 2023 | 9000 | 0.390 |
Why?
| | Magnetic Resonance Imaging | 8 | 2021 | 3174 | 0.390 |
Why?
| | Risk | 5 | 2022 | 853 | 0.380 |
Why?
| | Gamma Rays | 2 | 2021 | 52 | 0.380 |
Why?
| | Tissue Donors | 14 | 2005 | 336 | 0.380 |
Why?
| | Sweden | 3 | 2021 | 63 | 0.370 |
Why?
| | Adolescent | 14 | 2022 | 18480 | 0.370 |
Why?
| | Neoplastic Syndromes, Hereditary | 1 | 2010 | 29 | 0.370 |
Why?
| | Portal System | 6 | 2020 | 15 | 0.370 |
Why?
| | Chemoradiotherapy | 2 | 2022 | 200 | 0.370 |
Why?
| | Deoxycytidine | 6 | 2023 | 136 | 0.360 |
Why?
| | Neoplasm Grading | 4 | 2020 | 258 | 0.360 |
Why?
| | Decision Making | 1 | 2016 | 809 | 0.350 |
Why?
| | Young Adult | 11 | 2022 | 10793 | 0.350 |
Why?
| | Kidney | 2 | 2016 | 1353 | 0.340 |
Why?
| | Mass Screening | 2 | 2019 | 1052 | 0.340 |
Why?
| | Propensity Score | 2 | 2022 | 242 | 0.340 |
Why?
| | Age Factors | 6 | 2022 | 2995 | 0.330 |
Why?
| | Population Surveillance | 2 | 2019 | 413 | 0.330 |
Why?
| | Benchmarking | 2 | 2020 | 172 | 0.330 |
Why?
| | Software | 2 | 2017 | 613 | 0.330 |
Why?
| | Tumor Burden | 2 | 2022 | 274 | 0.330 |
Why?
| | Fluorouracil | 5 | 2021 | 151 | 0.310 |
Why?
| | Graft Survival | 12 | 2005 | 504 | 0.310 |
Why?
| | Laparoscopy | 3 | 2021 | 417 | 0.310 |
Why?
| | Survival Analysis | 11 | 2019 | 1267 | 0.300 |
Why?
| | Islets of Langerhans Transplantation | 3 | 2020 | 68 | 0.300 |
Why?
| | Internationality | 4 | 2020 | 152 | 0.290 |
Why?
| | Genetic Predisposition to Disease | 6 | 2019 | 2275 | 0.290 |
Why?
| | Lymphocytes, Tumor-Infiltrating | 2 | 2018 | 112 | 0.290 |
Why?
| | Family Health | 1 | 2007 | 201 | 0.290 |
Why?
| | Disease-Free Survival | 5 | 2023 | 649 | 0.290 |
Why?
| | Multidetector Computed Tomography | 2 | 2016 | 27 | 0.280 |
Why?
| | Length of Stay | 5 | 2021 | 1032 | 0.280 |
Why?
| | Pedigree | 3 | 2014 | 485 | 0.280 |
Why?
| | Adenoma | 2 | 2020 | 191 | 0.280 |
Why?
| | Predictive Value of Tests | 4 | 2021 | 1868 | 0.270 |
Why?
| | Cyst Fluid | 2 | 2022 | 27 | 0.270 |
Why?
| | Immunohistochemistry | 5 | 2019 | 1691 | 0.260 |
Why?
| | Proportional Hazards Models | 4 | 2023 | 1125 | 0.260 |
Why?
| | Chemoradiotherapy, Adjuvant | 3 | 2019 | 42 | 0.250 |
Why?
| | Leucovorin | 2 | 2021 | 43 | 0.250 |
Why?
| | Time Factors | 10 | 2021 | 6412 | 0.240 |
Why?
| | Prevalence | 3 | 2023 | 2326 | 0.240 |
Why?
| | Drainage | 9 | 2013 | 157 | 0.240 |
Why?
| | Liver Neoplasms | 2 | 2019 | 527 | 0.230 |
Why?
| | Metastasectomy | 1 | 2023 | 12 | 0.230 |
Why?
| | Pilot Projects | 5 | 2023 | 1419 | 0.230 |
Why?
| | Incidental Findings | 2 | 2021 | 80 | 0.230 |
Why?
| | Hospital Mortality | 4 | 2020 | 814 | 0.230 |
Why?
| | Reoperation | 7 | 2018 | 557 | 0.230 |
Why?
| | Hyperemia | 1 | 2023 | 43 | 0.230 |
Why?
| | Stomach Neoplasms | 1 | 2023 | 67 | 0.220 |
Why?
| | Hyperamylasemia | 1 | 2022 | 3 | 0.220 |
Why?
| | Microbiota | 2 | 2021 | 656 | 0.220 |
Why?
| | STAT3 Transcription Factor | 2 | 2022 | 189 | 0.210 |
Why?
| | Japan | 4 | 2023 | 97 | 0.210 |
Why?
| | Multicenter Studies as Topic | 1 | 2023 | 253 | 0.210 |
Why?
| | Carcinoma, Acinar Cell | 1 | 2021 | 5 | 0.210 |
Why?
| | Forecasting | 1 | 2023 | 353 | 0.210 |
Why?
| | Angiotensin Receptor Antagonists | 1 | 2022 | 84 | 0.200 |
Why?
| | Biliary Tract Surgical Procedures | 1 | 2021 | 27 | 0.200 |
Why?
| | Pathology, Clinical | 1 | 2021 | 31 | 0.200 |
Why?
| | Cysts | 1 | 2022 | 93 | 0.200 |
Why?
| | Datasets as Topic | 1 | 2021 | 103 | 0.200 |
Why?
| | ADAM10 Protein | 1 | 2021 | 28 | 0.200 |
Why?
| | Surgical Mesh | 1 | 2021 | 41 | 0.190 |
Why?
| | Fusobacterium nucleatum | 1 | 2020 | 3 | 0.190 |
Why?
| | Fusobacterium Infections | 1 | 2020 | 6 | 0.190 |
Why?
| | Digestive System Surgical Procedures | 1 | 2021 | 91 | 0.190 |
Why?
| | Amyloid Precursor Protein Secretases | 1 | 2021 | 76 | 0.190 |
Why?
| | Microdissection | 2 | 2011 | 13 | 0.190 |
Why?
| | Oligonucleotides, Antisense | 1 | 2020 | 100 | 0.190 |
Why?
| | Cyclosporine | 4 | 2005 | 173 | 0.180 |
Why?
| | Blood | 1 | 2020 | 100 | 0.180 |
Why?
| | Antimetabolites, Antineoplastic | 2 | 2010 | 83 | 0.180 |
Why?
| | Myeloid-Derived Suppressor Cells | 1 | 2020 | 57 | 0.180 |
Why?
| | Peritoneal Neoplasms | 1 | 2020 | 53 | 0.180 |
Why?
| | Conservative Treatment | 1 | 2020 | 31 | 0.180 |
Why?
| | Cystadenocarcinoma, Serous | 1 | 2020 | 49 | 0.180 |
Why?
| | Antibodies, Bacterial | 1 | 2020 | 126 | 0.180 |
Why?
| | Radiation Injuries | 1 | 2021 | 131 | 0.180 |
Why?
| | Comorbidity | 2 | 2022 | 1527 | 0.180 |
Why?
| | Dilatation | 1 | 2019 | 56 | 0.170 |
Why?
| | Lasers | 2 | 2011 | 124 | 0.170 |
Why?
| | Immunosuppressive Agents | 6 | 2005 | 681 | 0.170 |
Why?
| | Elective Surgical Procedures | 1 | 2020 | 160 | 0.170 |
Why?
| | Epithelial-Mesenchymal Transition | 1 | 2021 | 176 | 0.170 |
Why?
| | Saliva | 1 | 2020 | 188 | 0.170 |
Why?
| | Patient Care Team | 3 | 2020 | 521 | 0.170 |
Why?
| | Biliary Tract Diseases | 1 | 2019 | 35 | 0.170 |
Why?
| | Bacterial Infections | 1 | 2021 | 227 | 0.170 |
Why?
| | Laparotomy | 2 | 2016 | 106 | 0.170 |
Why?
| | Mouth | 1 | 2019 | 74 | 0.170 |
Why?
| | Insulin | 8 | 2013 | 2162 | 0.170 |
Why?
| | Gene Expression Regulation, Neoplastic | 4 | 2019 | 1167 | 0.170 |
Why?
| | Organ Culture Techniques | 1 | 2019 | 149 | 0.170 |
Why?
| | Sensitivity and Specificity | 2 | 2021 | 1795 | 0.170 |
Why?
| | Bile Ducts | 1 | 2019 | 73 | 0.170 |
Why?
| | Nutritional Support | 1 | 2018 | 28 | 0.160 |
Why?
| | Fibrosis | 1 | 2021 | 483 | 0.160 |
Why?
| | DNA Damage | 1 | 2021 | 357 | 0.160 |
Why?
| | Societies, Medical | 2 | 2020 | 703 | 0.160 |
Why?
| | Iopamidol | 2 | 2016 | 13 | 0.160 |
Why?
| | Carcinoma | 1 | 2019 | 204 | 0.160 |
Why?
| | Jejunum | 2 | 2016 | 30 | 0.160 |
Why?
| | Recombinant Fusion Proteins | 4 | 2005 | 653 | 0.160 |
Why?
| | Malnutrition | 1 | 2018 | 66 | 0.150 |
Why?
| | DNA, Bacterial | 1 | 2019 | 314 | 0.150 |
Why?
| | Logistic Models | 2 | 2020 | 1901 | 0.150 |
Why?
| | Kaplan-Meier Estimate | 2 | 2016 | 842 | 0.150 |
Why?
| | Radiosurgery | 1 | 2020 | 318 | 0.150 |
Why?
| | Machine Learning | 1 | 2020 | 331 | 0.150 |
Why?
| | Biliary Tract Neoplasms | 1 | 2016 | 20 | 0.150 |
Why?
| | Hepatic Duct, Common | 1 | 2016 | 6 | 0.140 |
Why?
| | Jaundice, Obstructive | 1 | 2016 | 3 | 0.140 |
Why?
| | Cholangiopancreatography, Magnetic Resonance | 1 | 2016 | 16 | 0.140 |
Why?
| | Hyperglycemia | 1 | 2020 | 312 | 0.140 |
Why?
| | Epitopes | 1 | 2018 | 443 | 0.140 |
Why?
| | Triiodobenzoic Acids | 1 | 2016 | 13 | 0.140 |
Why?
| | Cannabis | 1 | 2023 | 382 | 0.140 |
Why?
| | Sex Factors | 1 | 2022 | 1781 | 0.140 |
Why?
| | Organ Preservation Solutions | 3 | 2005 | 44 | 0.140 |
Why?
| | Cholangitis, Sclerosing | 1 | 2016 | 75 | 0.140 |
Why?
| | Printing, Three-Dimensional | 1 | 2016 | 63 | 0.140 |
Why?
| | Embolization, Therapeutic | 1 | 2018 | 192 | 0.140 |
Why?
| | Radiographic Image Enhancement | 1 | 2016 | 65 | 0.140 |
Why?
| | Bacteriocins | 1 | 2015 | 1 | 0.130 |
Why?
| | Hepatitis B | 1 | 2016 | 52 | 0.130 |
Why?
| | Organ Preservation | 3 | 2004 | 67 | 0.130 |
Why?
| | Genes, BRCA2 | 1 | 2015 | 25 | 0.130 |
Why?
| | Recovery of Function | 1 | 2019 | 604 | 0.130 |
Why?
| | Genes, BRCA1 | 1 | 2015 | 31 | 0.130 |
Why?
| | Diabetes Mellitus, Type 1 | 10 | 2010 | 3360 | 0.130 |
Why?
| | Interferon-gamma | 1 | 2018 | 736 | 0.130 |
Why?
| | Pneumonia, Viral | 1 | 2020 | 348 | 0.130 |
Why?
| | Coronavirus Infections | 1 | 2020 | 339 | 0.130 |
Why?
| | Papilloma, Intraductal | 1 | 2014 | 3 | 0.130 |
Why?
| | Heredity | 1 | 2014 | 11 | 0.130 |
Why?
| | Membrane Proteins | 1 | 2021 | 1055 | 0.120 |
Why?
| | Genomics | 2 | 2017 | 706 | 0.120 |
Why?
| | Neoplasm, Residual | 1 | 2014 | 103 | 0.120 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2017 | 453 | 0.120 |
Why?
| | Amylases | 1 | 2013 | 14 | 0.120 |
Why?
| | Antibodies, Monoclonal | 4 | 2005 | 1284 | 0.120 |
Why?
| | Reproducibility of Results | 6 | 2019 | 2874 | 0.120 |
Why?
| | Risk Adjustment | 1 | 2014 | 79 | 0.120 |
Why?
| | Tissue and Organ Harvesting | 5 | 2005 | 67 | 0.120 |
Why?
| | Immunotherapy, Adoptive | 1 | 2016 | 191 | 0.120 |
Why?
| | Perception | 1 | 2016 | 314 | 0.120 |
Why?
| | Virus Diseases | 1 | 2016 | 198 | 0.120 |
Why?
| | Tacrolimus | 2 | 2005 | 151 | 0.120 |
Why?
| | Severity of Illness Index | 3 | 2019 | 2674 | 0.120 |
Why?
| | Abdomen | 2 | 2004 | 110 | 0.120 |
Why?
| | Precision Medicine | 1 | 2017 | 363 | 0.120 |
Why?
| | Liver Transplantation | 3 | 2013 | 847 | 0.120 |
Why?
| | MicroRNAs | 2 | 2010 | 637 | 0.120 |
Why?
| | Cell Proliferation | 5 | 2021 | 2275 | 0.120 |
Why?
| | Syndrome | 1 | 2014 | 344 | 0.120 |
Why?
| | Cystadenoma, Mucinous | 1 | 2013 | 12 | 0.110 |
Why?
| | Diagnostic Imaging | 1 | 2015 | 294 | 0.110 |
Why?
| | Imaging, Three-Dimensional | 1 | 2016 | 499 | 0.110 |
Why?
| | Cadaver | 8 | 2005 | 327 | 0.110 |
Why?
| | Insulin-Secreting Cells | 2 | 2007 | 330 | 0.110 |
Why?
| | Surveys and Questionnaires | 3 | 2020 | 4708 | 0.110 |
Why?
| | Diagnostic Errors | 1 | 2014 | 162 | 0.110 |
Why?
| | Apoptosis | 5 | 2021 | 2484 | 0.110 |
Why?
| | Catheter Ablation | 1 | 2015 | 286 | 0.110 |
Why?
| | Endoscopy | 1 | 2014 | 272 | 0.100 |
Why?
| | Receptors, Antigen, T-Cell | 1 | 2016 | 632 | 0.100 |
Why?
| | Biomarkers | 1 | 2022 | 3588 | 0.100 |
Why?
| | Practice Patterns, Physicians' | 1 | 2020 | 1200 | 0.100 |
Why?
| | C-Reactive Protein | 1 | 2013 | 360 | 0.100 |
Why?
| | Preoperative Care | 1 | 2014 | 332 | 0.100 |
Why?
| | Cross-Sectional Studies | 1 | 2022 | 4552 | 0.100 |
Why?
| | Loss of Heterozygosity | 1 | 2011 | 40 | 0.100 |
Why?
| | Carcinoma in Situ | 1 | 2011 | 45 | 0.100 |
Why?
| | Kruppel-Like Transcription Factors | 1 | 2011 | 56 | 0.100 |
Why?
| | Graft Rejection | 5 | 2005 | 555 | 0.100 |
Why?
| | Tissue and Organ Procurement | 2 | 2004 | 248 | 0.100 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2016 | 702 | 0.100 |
Why?
| | Raffinose | 3 | 2005 | 20 | 0.090 |
Why?
| | Disaccharides | 3 | 2005 | 18 | 0.090 |
Why?
| | Glucose | 3 | 2020 | 953 | 0.090 |
Why?
| | Lung Neoplasms | 1 | 2023 | 2220 | 0.090 |
Why?
| | Mannitol | 3 | 2005 | 34 | 0.090 |
Why?
| | Histidine | 3 | 2005 | 63 | 0.090 |
Why?
| | Electrolytes | 3 | 2005 | 59 | 0.090 |
Why?
| | Glutamates | 3 | 2005 | 60 | 0.090 |
Why?
| | Allopurinol | 3 | 2005 | 82 | 0.090 |
Why?
| | Duodenum | 1 | 2010 | 67 | 0.090 |
Why?
| | Peptides | 1 | 2015 | 879 | 0.090 |
Why?
| | Quality of Health Care | 1 | 2014 | 586 | 0.090 |
Why?
| | Tumor Cells, Cultured | 2 | 2021 | 874 | 0.080 |
Why?
| | Intra-Abdominal Fat | 1 | 2009 | 98 | 0.080 |
Why?
| | Glutathione | 3 | 2005 | 324 | 0.080 |
Why?
| | Magnetic Resonance Angiography | 1 | 2010 | 210 | 0.080 |
Why?
| | Down-Regulation | 1 | 2011 | 627 | 0.080 |
Why?
| | Adenosine | 3 | 2005 | 211 | 0.080 |
Why?
| | T-Lymphocytes, Regulatory | 2 | 2022 | 359 | 0.080 |
Why?
| | Enzyme Replacement Therapy | 2 | 2018 | 10 | 0.080 |
Why?
| | Germ-Line Mutation | 2 | 2019 | 134 | 0.080 |
Why?
| | United States | 2 | 2021 | 12555 | 0.080 |
Why?
| | Morbidity | 2 | 2019 | 296 | 0.080 |
Why?
| | Diabetic Retinopathy | 2 | 2006 | 160 | 0.080 |
Why?
| | Gliclazide | 1 | 2007 | 1 | 0.080 |
Why?
| | ErbB Receptors | 1 | 2010 | 569 | 0.080 |
Why?
| | Child, Preschool | 2 | 2019 | 9491 | 0.070 |
Why?
| | Clinical Decision-Making | 2 | 2020 | 278 | 0.070 |
Why?
| | Consensus | 2 | 2020 | 534 | 0.070 |
Why?
| | Cytotoxicity, Immunologic | 2 | 2018 | 204 | 0.070 |
Why?
| | Tumor Microenvironment | 2 | 2020 | 454 | 0.070 |
Why?
| | Arterial Occlusive Diseases | 1 | 2007 | 74 | 0.070 |
Why?
| | Equilibrative Nucleoside Transporter 1 | 1 | 2006 | 12 | 0.070 |
Why?
| | Blood Loss, Surgical | 1 | 2007 | 87 | 0.070 |
Why?
| | C-Peptide | 1 | 2007 | 137 | 0.070 |
Why?
| | Extracorporeal Circulation | 1 | 2006 | 15 | 0.070 |
Why?
| | Alcohol Drinking | 2 | 2013 | 652 | 0.070 |
Why?
| | Hepatic Veins | 1 | 2006 | 31 | 0.070 |
Why?
| | Lacerations | 1 | 2006 | 30 | 0.070 |
Why?
| | Drug Resistance, Neoplasm | 1 | 2010 | 671 | 0.070 |
Why?
| | Vena Cava, Inferior | 1 | 2006 | 55 | 0.070 |
Why?
| | Transplantation, Autologous | 1 | 2006 | 191 | 0.070 |
Why?
| | Neovascularization, Pathologic | 1 | 2007 | 287 | 0.060 |
Why?
| | Jehovah's Witnesses | 1 | 2004 | 1 | 0.060 |
Why?
| | Abdominal Injuries | 1 | 2006 | 119 | 0.060 |
Why?
| | Bezoars | 1 | 2004 | 4 | 0.060 |
Why?
| | Smoking | 2 | 2013 | 1487 | 0.060 |
Why?
| | Contrast Media | 3 | 2016 | 373 | 0.060 |
Why?
| | Intestinal Obstruction | 1 | 2004 | 41 | 0.060 |
Why?
| | RNA, Messenger | 5 | 2011 | 2657 | 0.060 |
Why?
| | Splenectomy | 1 | 2024 | 57 | 0.060 |
Why?
| | Cystectomy | 1 | 2003 | 32 | 0.060 |
Why?
| | Consensus Development Conferences as Topic | 1 | 2023 | 32 | 0.060 |
Why?
| | Biopsy | 3 | 2019 | 1079 | 0.060 |
Why?
| | Chemotaxis | 1 | 2004 | 137 | 0.060 |
Why?
| | Ileum | 1 | 2003 | 100 | 0.060 |
Why?
| | Intestine, Small | 1 | 2004 | 131 | 0.060 |
Why?
| | Postoperative Period | 2 | 2019 | 309 | 0.060 |
Why?
| | Antioxidants | 1 | 2007 | 564 | 0.060 |
Why?
| | Intraoperative Complications | 1 | 2004 | 132 | 0.060 |
Why?
| | Child | 3 | 2019 | 19129 | 0.060 |
Why?
| | Lymphatic Metastasis | 1 | 2024 | 307 | 0.060 |
Why?
| | Gastrectomy | 1 | 2023 | 82 | 0.050 |
Why?
| | ROC Curve | 2 | 2014 | 473 | 0.050 |
Why?
| | Wounds, Nonpenetrating | 1 | 2006 | 285 | 0.050 |
Why?
| | Propylamines | 1 | 2022 | 12 | 0.050 |
Why?
| | Genetic Testing | 1 | 2005 | 389 | 0.050 |
Why?
| | Carbohydrates | 1 | 2022 | 59 | 0.050 |
Why?
| | Azathioprine | 1 | 2001 | 51 | 0.050 |
Why?
| | Urinary Bladder | 1 | 2003 | 180 | 0.050 |
Why?
| | Creatinine | 4 | 2004 | 491 | 0.050 |
Why?
| | Mycophenolic Acid | 1 | 2001 | 79 | 0.050 |
Why?
| | Cell Line, Tumor | 3 | 2018 | 2851 | 0.050 |
Why?
| | Retroperitoneal Space | 3 | 2005 | 15 | 0.050 |
Why?
| | Vascular Diseases | 1 | 2004 | 241 | 0.050 |
Why?
| | Mice, Inbred C57BL | 2 | 2021 | 4908 | 0.050 |
Why?
| | Urinary Bladder Neoplasms | 1 | 2003 | 211 | 0.050 |
Why?
| | Steroids | 1 | 2001 | 153 | 0.050 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 3 | 2011 | 982 | 0.050 |
Why?
| | Endoscopy, Gastrointestinal | 1 | 2023 | 202 | 0.050 |
Why?
| | Ephrin-B2 | 1 | 2021 | 42 | 0.050 |
Why?
| | Microbial Viability | 1 | 2021 | 81 | 0.050 |
Why?
| | Mice | 3 | 2022 | 15520 | 0.050 |
Why?
| | Diagnosis, Computer-Assisted | 1 | 2020 | 66 | 0.050 |
Why?
| | Cytoreduction Surgical Procedures | 1 | 2020 | 40 | 0.050 |
Why?
| | Capecitabine | 1 | 2019 | 46 | 0.050 |
Why?
| | Margins of Excision | 1 | 2019 | 31 | 0.050 |
Why?
| | Florida | 1 | 2020 | 73 | 0.050 |
Why?
| | Secretin | 2 | 2010 | 4 | 0.050 |
Why?
| | Hematopoietic Stem Cell Transplantation | 1 | 2005 | 540 | 0.040 |
Why?
| | Republic of Korea | 1 | 2019 | 26 | 0.040 |
Why?
| | Matched-Pair Analysis | 1 | 2019 | 39 | 0.040 |
Why?
| | Asia | 1 | 2019 | 54 | 0.040 |
Why?
| | Hyperthermia, Induced | 1 | 2020 | 67 | 0.040 |
Why?
| | Treatment Failure | 3 | 2005 | 341 | 0.040 |
Why?
| | International Cooperation | 1 | 2020 | 177 | 0.040 |
Why?
| | Acute Disease | 1 | 2022 | 940 | 0.040 |
Why?
| | Cell Death | 1 | 2021 | 339 | 0.040 |
Why?
| | Area Under Curve | 1 | 2019 | 296 | 0.040 |
Why?
| | Aquaporin 1 | 1 | 2018 | 5 | 0.040 |
Why?
| | Mice, Nude | 1 | 2020 | 663 | 0.040 |
Why?
| | Stromal Cells | 1 | 2019 | 102 | 0.040 |
Why?
| | Cells, Cultured | 3 | 2016 | 4077 | 0.040 |
Why?
| | Radiotherapy | 1 | 2019 | 187 | 0.040 |
Why?
| | Pancreatic Elastase | 1 | 2018 | 74 | 0.040 |
Why?
| | Cause of Death | 3 | 2005 | 380 | 0.040 |
Why?
| | Congresses as Topic | 1 | 2020 | 204 | 0.040 |
Why?
| | Xenograft Model Antitumor Assays | 1 | 2021 | 740 | 0.040 |
Why?
| | Anastomosis, Roux-en-Y | 2 | 2010 | 27 | 0.040 |
Why?
| | Hospitals, High-Volume | 1 | 2018 | 42 | 0.040 |
Why?
| | Anastomotic Leak | 1 | 2017 | 29 | 0.040 |
Why?
| | Preoperative Period | 1 | 2018 | 110 | 0.040 |
Why?
| | Multivariate Analysis | 2 | 2013 | 1474 | 0.040 |
Why?
| | Observer Variation | 1 | 2018 | 309 | 0.040 |
Why?
| | Robotic Surgical Procedures | 1 | 2019 | 89 | 0.040 |
Why?
| | Betacoronavirus | 1 | 2020 | 254 | 0.040 |
Why?
| | Perioperative Care | 1 | 2018 | 132 | 0.040 |
Why?
| | Patient Safety | 1 | 2020 | 281 | 0.040 |
Why?
| | Lymph Nodes | 1 | 2019 | 455 | 0.040 |
Why?
| | Oligonucleotide Array Sequence Analysis | 2 | 2010 | 770 | 0.040 |
Why?
| | Intestinal Neoplasms | 1 | 2016 | 23 | 0.040 |
Why?
| | Diabetic Nephropathies | 3 | 2005 | 289 | 0.040 |
Why?
| | Cholangiocarcinoma | 1 | 2016 | 38 | 0.040 |
Why?
| | Cell Movement | 1 | 2021 | 896 | 0.040 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 1 | 2017 | 237 | 0.040 |
Why?
| | Drug Therapy, Combination | 3 | 2004 | 965 | 0.030 |
Why?
| | Principal Component Analysis | 1 | 2016 | 180 | 0.030 |
Why?
| | Mass Spectrometry | 1 | 2019 | 681 | 0.030 |
Why?
| | Feces | 1 | 2018 | 396 | 0.030 |
Why?
| | Anastomosis, Surgical | 1 | 2016 | 146 | 0.030 |
Why?
| | Nutritional Status | 1 | 2018 | 300 | 0.030 |
Why?
| | Transplantation, Homologous | 2 | 2010 | 415 | 0.030 |
Why?
| | Vitamins | 1 | 2017 | 158 | 0.030 |
Why?
| | Research Design | 1 | 2021 | 969 | 0.030 |
Why?
| | Radiographic Image Interpretation, Computer-Assisted | 1 | 2016 | 109 | 0.030 |
Why?
| | Extracellular Matrix | 1 | 2019 | 446 | 0.030 |
Why?
| | Animals | 3 | 2022 | 33381 | 0.030 |
Why?
| | Flow Cytometry | 1 | 2018 | 1085 | 0.030 |
Why?
| | Cell Line | 1 | 2021 | 2707 | 0.030 |
Why?
| | Radiation Dosage | 1 | 2016 | 147 | 0.030 |
Why?
| | Anatomy, Cross-Sectional | 1 | 2014 | 12 | 0.030 |
Why?
| | Intraoperative Care | 1 | 2014 | 39 | 0.030 |
Why?
| | Feasibility Studies | 1 | 2017 | 749 | 0.030 |
Why?
| | Antigens, Neoplasm | 1 | 2016 | 228 | 0.030 |
Why?
| | Bacteria | 1 | 2021 | 757 | 0.030 |
Why?
| | Kidney Failure, Chronic | 3 | 2004 | 516 | 0.030 |
Why?
| | Systemic Inflammatory Response Syndrome | 1 | 2014 | 75 | 0.030 |
Why?
| | Immunologic Memory | 1 | 2016 | 313 | 0.030 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2017 | 455 | 0.030 |
Why?
| | Biomedical Research | 1 | 2019 | 612 | 0.030 |
Why?
| | Neoplasms | 1 | 2007 | 2179 | 0.030 |
Why?
| | Indole Alkaloids | 1 | 2013 | 11 | 0.030 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2010 | 1945 | 0.030 |
Why?
| | Drug Administration Schedule | 2 | 2005 | 736 | 0.030 |
Why?
| | Cytokines | 2 | 2016 | 1900 | 0.030 |
Why?
| | Drug Interactions | 2 | 2005 | 352 | 0.030 |
Why?
| | Algorithms | 1 | 2020 | 1541 | 0.030 |
Why?
| | Peptic Ulcer | 1 | 2013 | 14 | 0.030 |
Why?
| | Histocompatibility Testing | 2 | 2004 | 123 | 0.030 |
Why?
| | Global Health | 1 | 2015 | 310 | 0.030 |
Why?
| | Hypoxia | 1 | 2019 | 963 | 0.030 |
Why?
| | Asymptomatic Diseases | 1 | 2013 | 81 | 0.030 |
Why?
| | Safety | 2 | 2004 | 304 | 0.030 |
Why?
| | Postoperative Care | 1 | 2013 | 237 | 0.030 |
Why?
| | Pandemics | 1 | 2020 | 1355 | 0.030 |
Why?
| | Lymphocyte Activation | 1 | 2016 | 1067 | 0.030 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2017 | 1244 | 0.030 |
Why?
| | Anti-Bacterial Agents | 1 | 2021 | 1510 | 0.020 |
Why?
| | Carcinoma, Renal Cell | 1 | 2013 | 174 | 0.020 |
Why?
| | Microsatellite Repeats | 1 | 2011 | 143 | 0.020 |
Why?
| | Korea | 1 | 2010 | 8 | 0.020 |
Why?
| | In Situ Hybridization | 1 | 2011 | 311 | 0.020 |
Why?
| | Lung | 1 | 2023 | 3664 | 0.020 |
Why?
| | Cell Growth Processes | 1 | 2010 | 54 | 0.020 |
Why?
| | Matrix Metalloproteinase 2 | 1 | 2010 | 56 | 0.020 |
Why?
| | Odds Ratio | 1 | 2013 | 996 | 0.020 |
Why?
| | Biopsy, Needle | 1 | 2010 | 190 | 0.020 |
Why?
| | Blood Glucose | 3 | 2004 | 1939 | 0.020 |
Why?
| | Thyroid Neoplasms | 1 | 2013 | 278 | 0.020 |
Why?
| | Cardiovascular Diseases | 1 | 2001 | 1798 | 0.020 |
Why?
| | Matrix Metalloproteinase 9 | 1 | 2010 | 127 | 0.020 |
Why?
| | Edetic Acid | 1 | 2009 | 47 | 0.020 |
Why?
| | Pyridoxal Phosphate | 1 | 2009 | 21 | 0.020 |
Why?
| | PTEN Phosphohydrolase | 1 | 2010 | 143 | 0.020 |
Why?
| | Kidney Neoplasms | 1 | 2013 | 334 | 0.020 |
Why?
| | Tetrazolium Salts | 1 | 2008 | 18 | 0.020 |
Why?
| | Proto-Oncogene Proteins c-akt | 1 | 2010 | 420 | 0.020 |
Why?
| | Thiazoles | 1 | 2008 | 121 | 0.020 |
Why?
| | Surgical Procedures, Operative | 1 | 2010 | 215 | 0.020 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2010 | 527 | 0.020 |
Why?
| | Epigenesis, Genetic | 1 | 2011 | 539 | 0.020 |
Why?
| | Recurrence | 1 | 2010 | 975 | 0.020 |
Why?
| | bcl-2-Associated X Protein | 1 | 2007 | 46 | 0.020 |
Why?
| | Glyburide | 1 | 2007 | 36 | 0.020 |
Why?
| | Mutation | 1 | 2017 | 3457 | 0.020 |
Why?
| | Deoxycytidine Kinase | 1 | 2006 | 3 | 0.020 |
Why?
| | Microscopy, Electron | 1 | 2007 | 413 | 0.020 |
Why?
| | Ribonucleoside Diphosphate Reductase | 1 | 2006 | 5 | 0.020 |
Why?
| | Colorectal Neoplasms | 1 | 2013 | 628 | 0.020 |
Why?
| | Choledochostomy | 1 | 2006 | 7 | 0.020 |
Why?
| | Fluorescein Angiography | 1 | 2006 | 103 | 0.020 |
Why?
| | Motorcycles | 1 | 2006 | 7 | 0.020 |
Why?
| | Budd-Chiari Syndrome | 1 | 2006 | 9 | 0.020 |
Why?
| | 5'-Nucleotidase | 1 | 2006 | 34 | 0.020 |
Why?
| | Tyrosine | 1 | 2007 | 233 | 0.020 |
Why?
| | Prostatic Neoplasms | 1 | 2013 | 940 | 0.020 |
Why?
| | Proto-Oncogene Proteins c-bcl-2 | 1 | 2007 | 226 | 0.020 |
Why?
| | Cytidine Deaminase | 1 | 2006 | 57 | 0.020 |
Why?
| | Phosphorylation | 1 | 2010 | 1633 | 0.020 |
Why?
| | Hemorrhage | 1 | 2010 | 623 | 0.020 |
Why?
| | Proteomics | 1 | 2011 | 876 | 0.020 |
Why?
| | Economics, Pharmaceutical | 1 | 2005 | 10 | 0.020 |
Why?
| | Antilymphocyte Serum | 1 | 2005 | 66 | 0.020 |
Why?
| | Case-Control Studies | 1 | 2013 | 3171 | 0.020 |
Why?
| | Blood Group Incompatibility | 1 | 2005 | 15 | 0.020 |
Why?
| | Hepatectomy | 1 | 2006 | 139 | 0.020 |
Why?
| | Methylprednisolone | 1 | 2005 | 84 | 0.020 |
Why?
| | Fatal Outcome | 1 | 2006 | 287 | 0.020 |
Why?
| | Maximum Tolerated Dose | 1 | 2005 | 185 | 0.020 |
Why?
| | Visual Acuity | 1 | 2006 | 272 | 0.020 |
Why?
| | Accidents, Traffic | 1 | 2006 | 178 | 0.020 |
Why?
| | Glycerolphosphate Dehydrogenase | 1 | 2004 | 4 | 0.020 |
Why?
| | Isoantibodies | 1 | 2005 | 63 | 0.020 |
Why?
| | Fructose-Bisphosphate Aldolase | 1 | 2004 | 9 | 0.020 |
Why?
| | Glucokinase | 1 | 2004 | 13 | 0.020 |
Why?
| | Intraocular Pressure | 1 | 2006 | 275 | 0.020 |
Why?
| | Pyruvate Kinase | 1 | 2004 | 20 | 0.020 |
Why?
| | Pharmacogenetics | 1 | 2005 | 151 | 0.020 |
Why?
| | Diabetic Neuropathies | 1 | 2005 | 78 | 0.020 |
Why?
| | DNA Primers | 1 | 2005 | 533 | 0.020 |
Why?
| | Tissue Culture Techniques | 1 | 2004 | 67 | 0.020 |
Why?
| | Transcriptional Activation | 1 | 2006 | 348 | 0.020 |
Why?
| | Renal Circulation | 1 | 2004 | 75 | 0.020 |
Why?
| | Tumor Suppressor Proteins | 1 | 2006 | 289 | 0.010 |
Why?
| | Carcinoma, Transitional Cell | 1 | 2003 | 58 | 0.010 |
Why?
| | Kidney Function Tests | 1 | 2003 | 164 | 0.010 |
Why?
| | Monitoring, Physiologic | 1 | 2005 | 271 | 0.010 |
Why?
| | Cell Separation | 1 | 2004 | 296 | 0.010 |
Why?
| | Obesity, Morbid | 1 | 2005 | 197 | 0.010 |
Why?
| | Stents | 1 | 2006 | 457 | 0.010 |
Why?
| | Respiratory Insufficiency | 1 | 2006 | 290 | 0.010 |
Why?
| | In Vitro Techniques | 1 | 2004 | 1094 | 0.010 |
Why?
| | Thrombosis | 1 | 2005 | 309 | 0.010 |
Why?
| | Base Sequence | 1 | 2005 | 2159 | 0.010 |
Why?
| | Breast Neoplasms | 1 | 2013 | 1965 | 0.010 |
Why?
| | Glucocorticoids | 1 | 2005 | 545 | 0.010 |
Why?
| | Ischemia | 1 | 2004 | 374 | 0.010 |
Why?
| | Gene Expression | 1 | 2006 | 1489 | 0.010 |
Why?
| | Hemodynamics | 1 | 2004 | 1003 | 0.010 |
Why?
| | Blood Pressure | 1 | 2005 | 1664 | 0.010 |
Why?
| | Hypoglycemic Agents | 1 | 2005 | 1032 | 0.010 |
Why?
| | T-Lymphocytes | 1 | 2005 | 1774 | 0.010 |
Why?
| | Body Mass Index | 1 | 2004 | 2092 | 0.010 |
Why?
|
|
Del Chiaro's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|